Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma

NCT05422521 ·Status: RECRUITING ·Phase: NA

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

NCT01729104 ·Status: TERMINATED ·Phase: PHASE1

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

NCT02856646 ·Status: COMPLETED

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

NCT01045928 ·Status: TERMINATED ·Phase: PHASE1

Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America

NCT02559583 ·Status: COMPLETED

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00274924 ·Status: COMPLETED ·Phase: PHASE2

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

NCT00398177 ·Status: RECRUITING

Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.

NCT04621604 ·Status: TERMINATED ·Phase: NA

Home Hospital for Lymphoma

NCT04423848 ·Status: TERMINATED ·Phase: NA

Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9

NCT00400907 ·Status: UNKNOWN

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373 ·Status: RECRUITING ·Phase: PHASE2

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma

NCT00498043 ·Status: COMPLETED ·Phase: PHASE2

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733 ·Status: COMPLETED

Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

NCT02339805 ·Status: COMPLETED ·Phase: NA

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00005089 ·Status: COMPLETED ·Phase: PHASE2

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT04464798 ·Status: TERMINATED ·Phase: PHASE1

Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma

NCT06813573 ·Status: RECRUITING ·Phase: NA

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT05338892 ·Status: COMPLETED

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

NCT01007292 ·Status: COMPLETED ·Phase: PHASE2

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

NCT05751798 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00809341 ·Status: TERMINATED ·Phase: PHASE2

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

NCT00141700 ·Status: TERMINATED ·Phase: PHASE2

Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

NCT05464823 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA